Conversely, in the patients with low PRTN3 levels, patients with Bev-treated showed a trend towards improved survival compared to patients without Bev-treated (Supplementary Figure 4 ).
← all excerpts
High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
1
—
—